Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Mayo Clinic and Thermo Fisher Scientific have co-founded Precure, a new company aiming to build one of the world's largest biomedical datasets. Using molecular data from one million biospecimens and AI-driven analytics, Precure hopes to detect disease before symptoms appear and accelerate the development of new diagnostics and therapies.
Mayo Clinic and Thermo Fisher Scientific have joined forces to launch Precure, a new company with an ambitious goal: building one of the world's most comprehensive biomedical datasets. Mayo Clinic holds the majority stake and contributes clinical data and expertise, while Thermo Fisher — a minority owner — brings proteomics and mass spectrometry capabilities to the table.
Precure will draw on molecular data from one million biospecimens, combined with clinical records, wearable device data, and environmental exposure information. Using AI and large-scale analytics, the company aims to spot disease signals before symptoms ever appear — a potential game-changer for early diagnosis and precision medicine. The effort builds on Mayo Clinic's existing Precure Research initiative (launched July 2026) and a prospective study enrolling up to 100,000 participants, funded in part by Regeneron Pharmaceuticals.
By the Numbers:
Why it matters: Earlier disease detection could transform patient outcomes and reshape how drugs and diagnostics are developed — making this partnership a significant step toward population-scale precision medicine.
